Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
McKesson
Dow
Moodys

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Decitabine - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for decitabine and what is the scope of freedom to operate?

Decitabine is the generic ingredient in two branded drugs marketed by Otsuka Pharm Co Ltd, Accord Hlthcare, Chemi Spa, Cipla, Dr Reddys, Ingenus Pharms Llc, Lupin Ltd, Msn Labs Pvt Ltd, Pharmascience Inc, Sagent Pharms Inc, Sandoz Inc, Wockhardt Bio Ag, and Sun Pharma Global, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for decitabine. Fifteen suppliers are listed for this compound.

Drug Prices for decitabine

See drug prices for decitabine

Recent Clinical Trials for decitabine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rutgers, The State University of New JerseyPhase 2
Huihan WangN/A
ImmunoGen, Inc.Phase 1/Phase 2

See all decitabine clinical trials

Pharmacology for decitabine
Synonyms for decitabine
1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-
105597-46-4
123795-43-7
2-deoxyazacytidine
2-Desoxy-5-azacytidine
2'-Deoxy-5-azacytidine
2353-33-5
353A335
4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-on
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one
5-aza-2-deoxycytidine
5-Aza-2'-deoxycytidine
5-Aza-2'-deoxycytidine, >=97%
5-Aza-2'-deoxycytidine, 98%
5-Aza-2′-Deoxycytidine
5-aza-CdR
5-aza-dC
5-Aza-deoxycytidine
5-AZAdC
5-Azadeoxycytidine
5-Deoxy-2′-azacytidine
5A2dc
776B62CQ27
AB0020011
AB00918337_08
AB00918337-07
ABP001084
AC-1135
AC1L9PS9
ACT00147
AKOS015895047
ANW-25144
API0002229
AS-17558
AzadC
BC677683
BCP02870
BCP0726000271
BCP9000593
BDBM96274
BIFK0051
BRN 0617982
C-13049
C8H12N4O4
CA-714
CAS-2353-33-5
CC-26303
cc-571
CCG-208143
CCRIS 8227
CHEBI:50131
CHEMBL1201129
cid_451668
CS-0372
CTK1A2018
D03665
Dacogen
Dacogen (TN)
DB-029060
DB01262
decitabine (2 inverted exclamation marka-deoxy-5-azacytidine).cd
Decitabine (NSC127716, 5AZA-CdR)
Decitabine (USAN/INN)
Decitabine [USAN:INN:BAN]
deoxy-5-azacytidine
Dezocitidine
DSSTox_CID_10432
DSSTox_GSID_30432
DSSTox_RID_78849
DTXSID7030432
E-7373
EINECS 219-089-4
EOS114
EX-A961
FT-0082622
GTPL6805
HMS2235O03
HY-A0004
J-700084
J10097
JNJ 30979754
JNJ-30979754
KB-41703
MFCD00043011
MLS001332587
MLS001332588
MLS006010136
MolMap_000063
MolPort-003-925-958
NCGC_5ADOC
NCGC00166088-01
NCGC00166088-02
NCGC00166088-05
NSC 127716
NSC127716
PubChem19115
RL02744
s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-
s1200
SB18982
SC-19951
SCHEMBL4006
SMR000857076
SR-01000838879
SR-01000838879-4
SW218076-2
SYN3036
TL8001944
Tox21_112311
Tox21_112311_1
UNII-776B62CQ27
V0702
W-5049
XAUDJQYHKZQPEU-KVQBGUIXSA-N
ZINC16929327

US Patents and Regulatory Information for decitabine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sagent Pharms Inc DECITABINE decitabine INJECTABLE;INTRAVENOUS 207100-001 Mar 16, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Sandoz Inc DECITABINE decitabine INJECTABLE;INTRAVENOUS 202969-001 Aug 28, 2014 AP RX No No   Start Trial   Start Trial   Start Trial
Ingenus Pharms Llc DECITABINE decitabine INJECTABLE;INTRAVENOUS 210984-001 Sep 16, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Cipla DECITABINE decitabine INJECTABLE;INTRAVENOUS 208601-001 Nov 16, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
AstraZeneca
McKesson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.